Related Experiment Video

Updated: Jun 11, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment

Michael A Mohutsky1, Annette Romeike, Vince Meador

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Toxicologic Pathology
|July 10, 2010
PubMed

Insights

Drug metabolizing enzyme (DME) induction poses challenges in drug development, impacting efficacy and safety. Careful risk assessment and clinical trial vigilance are crucial for managing these hepatic DME induction risks.

Area of Science:

  • Pharmacology
  • Drug Development
  • Toxicology

Background:

  • Hepatic drug metabolizing enzyme (DME) induction presents significant challenges in pharmaceutical development.
  • These challenges include altered drug efficacy, reduced drug exposure due to autoinduction, and the potential formation of toxic metabolites.

Purpose of the Study:

  • To address the complexities and uncertainties in assessing the risk of hepatic DME induction during clinical drug development.
  • To highlight the importance of vigilance and specific studies for accurate drug risk assessment.

Main Methods:

  • Review of current understanding of hepatic DME induction and its clinical implications.
  • Emphasis on the role of in vitro and in vivo assessments in evaluating DME induction potential.
  • Discussion of the necessity for pharmacokinetic studies in the presence of concomitant medications and diseases.

Main Results:

  • Hepatic DME induction rarely causes overt clinical toxicity unless severe.
  • Higher drug doses and lower drug potency increase the likelihood of DME induction and drug-drug interactions.
  • Clinical trial vigilance and pharmacokinetic assessments are vital for risk profiling.

Conclusions:

  • A case-by-case approach, supported by advanced assessment technologies, is essential for developing safe and effective drugs.
  • Minimizing risks associated with hepatic DME induction is key to successful drug development and patient safety.

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...